N6-Methyladenosine Enhances the Translation of ENO1 to Promote the Progression of Bladder Cancer by Inhibiting PCNA Ubiquitination

Chengquan Shen,Jing Liu,Fei Xie,Yongbo Yu,Xiaocheng Ma,Ding Hu,Changxue Liu,Yonghua Wang
DOI: https://doi.org/10.1016/j.canlet.2024.217002
IF: 9.756
2024-01-01
Cancer Letters
Abstract:The mechanism underlying N6-methyladenosine (m6A) modification in bladder cancer (BC) remains elusive. We identified that the RBM15/METTL3 complex enhances m6A modification and promotes the ENO1 protein translation efficiency through its 359A site by depending on YTHDF1 in BC cells. In the tumor microenvironment, TGF-β effectively stimulates RBM15/METTL3 expression to improve ENO1 mRNA m6A modification through the Smad2/3 pathway. Reduced ENO1 m6A levels hamper tumor proliferation both in vitro and in vivo. Mechanistically, ENO1 augments PCNA protein stability by reducing its K48-linked ubiquitination and thus prevents protein degradation through the endoplasmic reticulum-associated degradation pathway. According to the subsequent experiments, the ENO1 inhibitor significantly reduced tumor proliferation both in vitro and in vivo. Our study highlights the significance of RBM15/METTL3 complex-mediated ENO1 mRNA m6A modification in ENO1 expression. It also reveals a novel mechanism by which ENO1 promotes BC progression, thereby suggesting that ENO1 can be a therapeutic target for BC.
What problem does this paper attempt to address?